GnuBIO (Cambridge, MA), a developmental-stage medical device company focused on next-generation DNA sequencing, closed a $10M Series B financing. Participants were not identified. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Strand Diagnostics (Indianapolis, IN) a commercial-stage molecular diagnostics company focused on DNA screening of breast and prostate biopsy samples and patient DNA for molecular cancer diagnosis verification, closed a $30M Series A financing. Participants include NantWorks. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

IntegenX (Pleasanton, CA) a commercial-stage device company focused on sample preparation for next generation sequencing, closed a $40M Series C financing. Participants include Essex Woodlands, Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, Rona Holdings, Samsung Ventures and In-Q-Tel.

PathoGenetix (Woburn, MA) a development-stage sequencing company focused on simultaneous identification and characterization of bacterial strains in a single test, closed a $7.5M Series B financing, bringing the total round to $11.5M. Participants include Ascension Health Ventures, Excel Venture Management, CB Health Ventures and HealthCare Ventures.

NABsys (Providence, RI) a development stage dna sequencing company focused on nanopore arrays that can do not require amplification or labeling, closed a $10M Series C financing. Participants include Stata Venture. Thanx for your patience as we catch-up.

Stratos Genomics (Seattle, WA) a development-stage device company focused on a ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics, closed a $2.1M Series A financing, bringing the total round to $6.1M. Participants have included Fisk Ventures. The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are [...]

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series D financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Redmile Group.

IntegenX (Pleasanton, CA) a commercial-stage device company focused on sample prep for next generation sequencing, closed a $15.6M Series B financing. Participants include Domain Associates, In-Q-Tel, RONAholdings, QuestMark Partners, Cross Creek Partners and Greenspring.

OpGen (Gaithersburg, MD) a commercial-stage genomics device company focused on optical mapping combining strain typing and sequencing, closed a $17M Series B round financing. Participants include jVen Capital, CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Versant Ventures.

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Pacific Biosciences (Menlo Park, CA) developer of single molecule real-time nucleic acid and protein sequencing system closed a $50M Series F financing. Participants include Gen-Probe, Monsanto, the Wellcome Trust, Sutter Hill Ventures, Deerfield Management, Intel Capital, Morgan Stanley, Redmile Group, T. Rowe Price, Mohr Davidow Ventures, Kleiner Perkins Caufield and Byers, Alloy Ventures, Maverick Capital, [...]

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series C financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Illumina.

NABsys (Providence, RI) a development-stage company focused on polymerase-free solid-state electronic detection DNA sequencing free of amplification or labeling focused point-of-care clinical use, closed a $7M Series B financing. Participants include Stata Venture Partners and Point Judith Capital. _________________________________________________________________________ NOTE: New OnBioVC Friday feature coming, well…this Friday!